Hypertrophic cardiomyopathy (HCM) is a heart disease in which the heart muscle thickens.
This condition puts an overload on the heart that can lead to cardiac arrest. Many patients rely on a multitude of medications to combat their symptoms.
The new drug called Mavacamten reduces abnormal contractions caused by genetic variants, directly attacking the underlying condition. Previously, doctors had to treat individual HCM symptoms one by one, often using a multitude of medications such as beta-blockers, antiarrhythmics, calcium channel blockers, and others. With Mavacamten it is a precise medicine, a multitude of medicines is no longer necessary.
Mavacamten is a molecule specifically developed for the treatment of patients with this disease and is indicated for adults.
The FDA certifies this medication to treat hypertrophic cardiomyopathy, as it is the only cardiac myosin inhibitor and is considered an excellent treatment for this progressive condition. In order to apply this type of treatment, it is essential to carry out echocardiogram evaluations of the left ventricle before and during treatment.
https://www.conexiones365.com/nota/expo-med/innovacion/8-avances-medicos-2023
